ZFZhao Fazhi

Zhao Fazhi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhao Fazhi has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Ding Zhi

    Department of Gastric Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center University of Electronic Science and Technology of China Chengdu Sichuan Province People's Republic of China

    1 shared publication
  • Jingnuo Ding

    Department of General Medicine Hospital of Chengdu University of Traditional Chinese Medicine Chengdu Sichuan Province People's Republic of China

    1 shared publication
  • Yan Chen

    Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu 610040, China

    1 shared publication
  • Zhang Huachuan

    Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center University of Electronic Science and Technology of China Chengdu Sichuan Province People's Republic of China

    1 shared publication
  • Zhou Da

    Department of Gastric Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center University of Electronic Science and Technology of China Chengdu Sichuan Province People's Republic of China

    1 shared publication

Latest Publications

  • Gastrointestinal Stromal Tumors: Molecular Mechanisms of Drug Resistance and Advances in Therapeutic Strategies

    by Ding Jingnuo, Zhang Huachuan, Zhou Da, Ding Zhi, Chen Yan, Zhao Fazhi

    Gastrointestinal stromal tumors (GISTs), the most common mesenchymal neoplasms of the digestive tract, are primarily driven by gain‐of‐function mutations in the receptor tyrosine kinases KIT or PDGFRA. The introduction of imatinib, a selective tyrosine kinase inhibitor (TKI), revolutionized the management of advanced GIST. However, the emergence of drug resistance remains a major clinical challenge, limiting long‐term efficacy. Resistance mechanisms are multifactorial, predominantly involving secondary mutations in KIT or PDGFRA that impair TKI binding or stabilize the kinase in an active conformation. Beyond genomic alterations, nonmutational adaptive responses—including dysregulation of noncoding RNAs, metabolic reprogramming, epigenetic modifications, and an immunosuppressive tumor microenvironment—significantly contribute to treatment failure. This review comprehensively analyzes these resistance pathways and discusses the evolution of therapeutic strategies toward precision medicine. Current approaches emphasize molecular subtype‐guided first‐line therapy, ctDNA‐driven sequencing of subsequent lines, and the use of novel TKIs (e.g., avapritinib, ripretinib, bezuclastinib) tailored to specific resistance mutations. Furthermore, we explore emerging modalities such as boron neutron capture therapy (BNCT), which offers a kinase‐independent mechanism to target resistant disease, and combination strategies that integrate immunotherapy, epigenetic modulators, and pathway‐specific inhibitors. Advances in liquid biopsy and molecular profiling are enabling real‐time adaptation of therapy, moving GIST management toward a dynamic, personalized paradigm aimed at overcoming resistance and improving patient outcomes.